252 results on '"Teishima, J."'
Search Results
2. Relationship between the localization of fibroblast growth factor 9 in prostate cancer cells and postoperative recurrence
3. Therapeutic efficacy of narrow band imaging-assisted transurethral electrocoagulation for ulcer-type interstitial cystitis/painful bladder syndrome: PO-04
4. Impact of low-intensity extracorporeal shock wave therapy on sexual function after non-nerve-sparing robot-assisted laparoscopic radical prostatectomy
5. Restration of IGFBP-rP1 in human prostate cancer
6. 318 - Longitudinal evaluation of health related quality of life following laparoscopic adrenalectomy: Impact of adrenalectomy on cortisol-producing adenoma
7. PT367 - Accurate clinical T3 staging by a computed tomography scoring system is an independent preoperative predictor of survival in patients with urothelial carcinoma of the ureter
8. 1155 - Improved prognosis for old-aged patients with metastatic renal cell carcinoma after targeted therapy
9. 851 - KIFC1 inhibitor CW069 induces apoptosis and reverses resistance to docetaxel in prostate cancer
10. 731 - Parallels between immunohistochemical classification of upper and lower tract urothelial carcinoma using markers of urothelial differentiation
11. 260 - PCDHB9 promotes resistance to bicalutamide and is associated with the survival of prostate cancer patients
12. 111 - Transcribed ultraconserved region Uc.63+ promotes resistance to docetaxel through AR signaling and a promising serum biomarker for docetaxel treatment in prostate cancer
13. 12 - Comparisons of surgeons’ and assistants’ fatigue after laparoendoscopic single-site versus conventional laparoscopic adrenalectomy: A single surgeon’s experience
14. 387 - Prognostic impact of immunohistochemical classification of bladder cancer according to luminal (Uroplakin III) and basal (Cytokeratin 5/6) markers
15. 1070 Regenerating islet-derived related protein 4 as candidate of a novel biomarker in castration-resistant prostate cancer patients
16. 853 Prevalence of hand joint symptoms of androgen deprivation therapy in Japanese prostate cancer patients
17. 669 A phase III, multicenter, randomized, controlled study of maximum androgen blockade with vs without zoledronic acid in prostate cancer patients with metastatic bone disease: Results of main secondary endpoints in ZAPCA trial
18. 485 Impact of spatial cognitive ability on the proficiency of urological surgeons in robot-assisted surgery using mimic dV-trainer
19. 47 Regeneration of rat corpus cavernosa tissue after transplantation of CD 133+ cells derived from human bone marrow and placement of biodegradable gel sponge sheet
20. 16 Comparison of clinicopathological features and prognosis in prostate cancer between atomic bomb survivors and control patients
21. 9 The impact of change in serum C-reactive protein level on the prediction of effects of molecular targeted therapy in metastatic renal cell carcinoma patients
22. 208 Regenerating islet-derived family, member 4 enhances cell proliferation, castration-resistance and chemoresistance through acceleration of neuroendocrine differentiation in human prostate cancer cells
23. P143 Usefulness of flomoxef in the prevention of infection complicating transrectal prostate needle biopsy
24. 666 Therapeutic efficacy of narrow band imaging-assisted transurethral electrocoagulation for ulcer-type interstitial cystitis/painful bladder syndrome
25. 462 Patient-reported satisfaction and cosmesis outcomes following laparoscopic adrenalectomy: LESS vs conventional laparoscopic surgery
26. 984 Prevalence of hand joint symptoms of androgen deprivation therapy in Japanese prostate cancer patients
27. 546 Localization of fibroblast growth factor 9 in prostate cancer cells Is associated with postoperative recurrence
28. 631 ROLE OF RADICAL PROSTATECTOMY FOR HIGH-RISK LOCALIZED PROSTATE CANCER
29. 218 TRENDS IN PERCEPTION OF MALE ERECTILE DYSFUNCTION DRUGS AMONG WOMEN IN THE GENERAL POPULATION IN JAPAN
30. 110 Combination therapy using molecular-targeted drugs inhibiting platelet-derived growth factor receptors in the tumor microenvironment of renal cell carcinoma.
31. 254 DSC2 IS A NEW IMMUNOHISTOCHEMICAL MARKER INDICATIVE OF SQUAMOUS CELL CARCINOMA COMPONENT IN URINARY BLADDER CANCER AND A VALUABLE PROGNOSTIC FACTOR
32. 493 Longitudinal evaluation of patient-reported cosmesis outcome following laparoscopic adrenalectomy: Laparoendoscopic single-site adrenalectomy vs conventional laparoscopic adrenalectomy.
33. 121 TSPAN8 expression in renal cell carcinoma is a poor prognostic factor and a novel therapeutic target.
34. Effects of modifying hinotori™ surgical robot system on perioperative outcome of robot-assisted radical prostatectomy.
35. Initial Experience of Robot Assisted Laparoscopic Pyeloplasty for Ureteropelvic Junction Obstruction Using the Hinotori Surgical Robot System.
36. Clinical Outcomes and Risk Stratification in Patients With Metastatic Hormone-Sensitive Prostate Cancer Treated With New-Generation Androgen Receptor Signaling Inhibitors.
37. Adrenalectomy for pheochromocytoma: Surgical outcomes and preoperative risk factors for hemodynamic instability.
38. Comparative clinical trials with a novel approach: Utilizing the shiny method for investigational urothelial carcinoma therapies.
39. Evaluating RB1 and p53 as diagnostic markers in treatment-related neuroendocrine prostate cancer through immunohistochemistry and genomic analysis of RB1 and TP53.
40. Temporal declines in bone mineral density and trabecular bone score during androgen deprivation therapy.
41. Efficacy of Combination Therapy With Radium-223 and Enzalutamide in Castration-resistant Prostate Cancer With Bone Metastases.
42. Therapeutic outcome of combination therapy using immune-checkpoint inhibitors and tyrosine kinase inhibitors for metastatic non-clear-cell renal cell carcinoma.
43. Prognostic factors among patients with pathological Grade Group 5 prostate cancer based on robot-associated radical prostatectomy specimens from a large Japanese cohort (MSUG94).
44. Prognostic model using postoperative normalization of C-reactive protein levels in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy.
45. Prognostic Importance of Lymphovascular Invasion for Specific Subgroup of Patients with Prostate Cancer After Robot-Assisted Radical Prostatectomy (The MSUG94 Group).
46. Multidisciplinary treatment for small cell carcinoma of the bladder: a case report.
47. Incidence and risk factors of inguinal hernia after robot-assisted radical prostatectomy: a retrospective multicenter cohort study in Japan (the MSUG94 group).
48. Impact of adjuvant chemotherapy for patients with locally advanced upper tract urothelial carcinoma in real-world clinical practice.
49. The Negative Impact of Inflammation-Related Parameters in Prostate Cancer after Robot-Assisted Radical Prostatectomy: A Retrospective Multicenter Cohort Study in Japan (the MSUG94 Group).
50. Early and late urinary continence outcomes after unilateral and bilateral nerve-sparing robot-assisted radical prostatectomy: A retrospective multicentre cohort study in Japan (the MSUG94 group).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.